METOPROLOL

Course overview

METOPROLOL IS FDA-APPROVED FOR THE TREATMENT OF ANGINA, HEART FAILURE, MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION/FLUTTER, AND HYPERTENSION. OFF-LABEL USES INCLUDE SUPRAVENTRICULAR TACHYCARDIA AND THYROID STORM. BOTH ORAL AND INTRAVENOUS PREPARATIONS ARE AVAILABLE. THERE ARE IMMEDIATE AND EXTENDED-RELEASE PREPARATIONS AVAILABLE ORALLY. THERE IS CONTROVERSY REGARDING THE SELECTION OF BETA-BLOCKERS IN THE MANAGEMENT OF THE ABOVE CONDITIONS. THERE ALSO IS CONFLICTING EVIDENCE REGARDING THE OPTIMAL CHOICE OF A PARTICULAR BETA-BLOCKER IN THE TREATMENT OF EACH SPECIFIC DISEASE. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, PHARMACOLOGY, MONITORING, AND RELEVANT INTERACTIONS OF METOPROLOL, PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE TREATMENT OF PATIENTS WITH CONDITIONS WHERE IT IS OF CLINICAL VALUE.